3685-22-1Relevant articles and documents
PNO ligand containing planar chiral ferrocene and axial chiral diphenol and application thereof
-
Paragraph 0128-0131, (2021/06/23)
The invention discloses a PNO ligand containing planar chiral ferrocene and axially chiral diphenol and application of the PNO ligand. The PNO ligand containing planar chiral ferrocene and axially chiral diphenol is shown in any one of general formulas (I)-(IV). Or a PNO ligand containing planar chiral ferrocene and axial chiral diphenol as shown in any one of general formulas (V)-(VIII); compared with a previously reported tridentate ligand, the PNO ligand containing the planar chiral ferrocene and the axial chiral diphenol not only has good stability and easiness in synthesis, but also has planar chirality and axial chirality and has a good chiral environment, so that not only is excellent selectivity to a substrate ensured, but also the catalytic activity of a catalyst and the application range of the substrate are further improved. The chiral raw materials used in the invention are commercial bulk products, and the ligand synthesis route is simpler, so that large-scale production can be well carried out, and the method has a huge commercial application prospect.
A Molecular Torsion Balance Study: A Nearby Anionic Group Exerts Little Influence on Hydrophobic Interactions between Nonpolar Surfaces
Ling, Xiujun,Wilcox, Craig S.
supporting information, p. 14010 - 14014 (2019/11/14)
Polar groups have a solvent ordering effect on water and therefore may affect hydrophobic binding energies for nearby lipophilic surfaces. This would mean that determinations of excess surface free energy association energies require consideration of nearby polar functional groups. This paper reports results of a study to measure this possible effect. It was concluded from the models used here that an anionic polar group nearby a hydrophobic surface has little or no effect on the magnitude of hydrophobic association.
DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY
-
Paragraph 1087; 1088, (2017/02/28)
The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.